Amerigo Scientific provides a diverse selection of depletion antibodies targeting surface proteins and cytokines, facilitating in vivo studies focusing on cell-specific depletion. Our commitment to quality ensures reliable results, enabling researchers to generate publication-grade data.
Natural depletion, as observed in conditions such as HIV infection, or induced depletion for therapeutic interventions, underscores the widespread use of in vivo experiments aimed at selectively removing specific cell types to elucidate their roles in diverse immunological processes and diseases. These antibodies are designed for in vivo applications where the injected depletion antibody targets and eliminates a specific cell type. Such experiments are valuable for validating and extending findings from genetic knockout mouse models or for elucidating the direct biological relevance of certain cell types. These antibodies facilitate cell elimination through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC).
Fig.1 Mechanism of action of cell-depleting therapeutic IgG antibodies in multiple sclerosis.1
Immunofluorescence Antibodies | ELISA and Immunoassays Antibodies |
Flow Cytometry Antibodies | Immunohistochemistry Antibodies |
Blocking and Neutralizing Antibodies | Activating Antibodies |
Immunoprecipitation Antibodies | Western Blot Antibodies |
Surface Plasmon Resonance Antibodies | Stimulatory Antibodies |
Amerigo Scientific has successfully developed a broad spectrum of immune cell-specific depletion antibodies targeting various molecules. For additional details and to explore opportunities for aligning with your research objectives, please
.Reference